2018
Brief Report
Yanik EL, Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Horberg MA, Moore RD, Mathews WC, Justice AC, Hessol NA, Mayor AM, Gill MJ, Brooks JT, Sun J, Althoff KN, Engels EA, Silverberg MJ, Dubrow R. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 499-504. PMID: 29771785, PMCID: PMC6037538, DOI: 10.1097/qai.0000000000001719.Peer-Reviewed Original ResearchConceptsMelanoma incidenceAntiretroviral therapyGeneral populationMelanoma riskNorth American AIDS Cohort CollaborationRelationship of immunosuppressionWhite general populationHIV RNA levelsStandardized incidence ratiosCutaneous melanoma incidenceUltraviolet B exposureHigher melanoma incidenceHigh UVB exposureCohort CollaborationSkin surveillanceCD4 countHIV RNAImmune dysfunctionIncidence ratiosCox regressionHIV replicationRisk factorsCalendar periodWhite raceClinical care
2004
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. The Lancet 2004, 364: 51-62. PMID: 15234856, DOI: 10.1016/s0140-6736(04)16589-6.Peer-Reviewed Original ResearchConceptsProportional hazards modelVirological failureCD4 cell count slopesHIV-1 RNA concentrationsCox proportional hazards modelCD4 cell countPredictors of deathAntiretroviral therapyHIV cohortDual therapyClinical outcomesViral loadHIV replicationDrug classesTreatment strategiesTreatment informationPatientsDemographic characteristicsRNA concentrationRegression analysisTherapyFailureCohort